<?xml version="1.0" encoding="UTF-8"?>
<p>The CYD14 and CYD15 intent-to-treat (ITT) cohorts consisted of all participants who received at least one injection [
 <xref rid="pone.0207878.ref009" ref-type="bibr">9</xref>,
 <xref rid="pone.0207878.ref010" ref-type="bibr">10</xref>]. Analysis of the ITT cohort included all symptomatic, virologically-confirmed dengue events between months 0 and 25 (end of the active follow-up phase). All analyses right-censored participants at month 25 or at dropout if it occurred earlier. The combined CYD14 + CYD15 analyses focused on the age range of the study populations for which CYD-TDV is licensed, 9â€“16 year-old children. Demographic characteristics of the population combining the two studies are displayed in 
 <xref ref-type="supplementary-material" rid="pone.0207878.s003">S1 Table</xref>.
</p>
